Premium
Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients
Author(s) -
Marczak Agnieszka,
Kowalczyk Aleksandra,
WrzesieńKus´ Agata,
Robak Tadeusz,
Jóźwiak Zofia
Publication year - 2006
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1016/j.cellbi.2005.09.001
Subject(s) - idarubicin , microviscosity , daunorubicin , doxorubicin , chemistry , pharmacology , anthracycline , lipid bilayer , lipid peroxide , drug , membrane fluidity , medicine , biochemistry , cancer , chemotherapy , antioxidant , lipid peroxidation , membrane , breast cancer , cytarabine
Doxorubicin (DOX) and idarubicin (IDA) are anthracycline antibiotics, widely used in human cancer treatment. The present study addressed the effects of these two drugs on lipid bilayer fluidity, protein conformation and microviscosity in erythrocytes from acute myeloid leukaemia patients, using electron spin resonance (ESR) spectroscopy and fluorescence measurements. Only DOX caused statistically significant changes in the parameters examined. Within 30 min of drug injection, changes were observed in the fluidity of the hydrophobic parts of the lipid bilayer and erythrocyte membrane protein conformation. These changes persisted for up to 24 h. Analysis of the EPR Tempamine spectrum also showed that the microviscosity of the erythrocyte interior increased during the early stages of the drug effect. Idarubicin, in contrast, caused no identifiable change in any of the parameters studied and therefore seems to be safe for erythrocytes. We conclude that IDA is markedly less toxic than DOX to erythrocytes from acute myeloid leukaemia patients.